Hormone receptor positive breast cancer
Authors: Dr Nicholas Zdenkowski BMed, FRACP, PhD
Institution: Hunter Valley Oncology, Newcastle, Australia
Introduction
Progress has been made recently in the management of estrogen-receptor positive, HER2-negative early stage breast cancer. This is reflected in reductions in recurrence and death from breast cancer. Decisions about treatment have become more complex. The emergence of data to support adjuvant CDK 4/6 inhibitors is being incorporated into routine practice. It has become more clear which patients will benefit from adjuvant chemotherapy, although the tools that we use remain imprecise and may not be accessible to all. Adjuvant zoledronic acid is a relatively low-cost strategy that is supported by data, but the implementation is variable. Duration of, and type of optimal endocrine therapy according to tumour and patient variables, will be presented. Clinical trials and the early data for neoadjuvant therapy with and without immunotherapy will also be discussed.
Methods
Progress has been made recently in the management of estrogen-receptor positive, HER2-negative early stage breast cancer. This is reflected in reductions in recurrence and death from breast cancer. Decisions about treatment have become more complex. The emergence of data to support adjuvant CDK 4/6 inhibitors is being incorporated into routine practice. It has become more clear which patients will benefit from adjuvant chemotherapy, although the tools that we use remain imprecise and may not be accessible to all. Adjuvant zoledronic acid is a relatively low-cost strategy that is supported by data, but the implementation is variable. Duration of, and type of optimal endocrine therapy according to tumour and patient variables, will be presented. Clinical trials and the early data for neoadjuvant therapy with and without immunotherapy will also be discussed.
Results
Progress has been made recently in the management of estrogen-receptor positive, HER2-negative early stage breast cancer. This is reflected in reductions in recurrence and death from breast cancer. Decisions about treatment have become more complex. The emergence of data to support adjuvant CDK 4/6 inhibitors is being incorporated into routine practice. It has become more clear which patients will benefit from adjuvant chemotherapy, although the tools that we use remain imprecise and may not be accessible to all. Adjuvant zoledronic acid is a relatively low-cost strategy that is supported by data, but the implementation is variable. Duration of, and type of optimal endocrine therapy according to tumour and patient variables, will be presented. Clinical trials and the early data for neoadjuvant therapy with and without immunotherapy will also be discussed.
Conclusion
Progress has been made recently in the management of estrogen-receptor positive, HER2-negative early stage breast cancer. This is reflected in reductions in recurrence and death from breast cancer. Decisions about treatment have become more complex. The emergence of data to support adjuvant CDK 4/6 inhibitors is being incorporated into routine practice. It has become more clear which patients will benefit from adjuvant chemotherapy, although the tools that we use remain imprecise and may not be accessible to all. Adjuvant zoledronic acid is a relatively low-cost strategy that is supported by data, but the implementation is variable. Duration of, and type of optimal endocrine therapy according to tumour and patient variables, will be presented. Clinical trials and the early data for neoadjuvant therapy with and without immunotherapy will also be discussed.
